Neurocrine Biosciences | NBIX - Spese Di Vendita E Di Amministrazione

Prezzo Delle Azioni
127.68
Cambio Giornaliero
-2.51 -1.93%
Mensile
-2.63%
Annuale
19.63%
Q2 Previsione
124.95




Spese Di Vendita E Di Amministrazione Cambiamento Data
AbbVie USD 3.89B 325M 2025-12
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Cytokinetics USD 91.72M 67.02M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Exelixis USD 123.02M 19.9M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Prothena USD 7.65M 5.59M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Repligen USD 74.36M 703K 2025-12
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12
Xoma USD 11M 2.54M 2024-06